GNRH1 and adenomyosis: Furthermore, certain high-risk populations (such as women with recurrent implantation failure, endometriosis or adenomyosis, as mentioned above) may derive particular benefit from luteal GnRH-a supplementation, as suggested by subgroup analyses and case series, but high-quality RCTs in these subgroups are lacking.